期刊文献+

血管内皮生长因子-C干扰对人类结肠癌裸鼠移植瘤模型淋巴管生成的影响 被引量:2

Effect of VEGF-C interfering on the lymphangiogenesis of a mouse model bearing human colon cancer
原文传递
导出
摘要 目的构建携带有RNA干扰片段的腺病毒载体Ad5F35-VEGF-C siRNA-EGFP,探讨人类结肠癌BALB/c裸鼠皮下移植瘤模型瘤内注射腺病毒载体Ad5F35-VEGF-C siRNA-EGFP抑制血管内皮生长因子-C(VEGF-C)表达、结肠癌生长以及结肠癌淋巴管生成的效果。方法选择针对人类VEGF-C mRNA的特异性siRNA靶序列,设计合成其相应的双链DNA,利用BamHI、HindⅢ双酶切插入pDC316-EGFP-U6载体后构建穿梭质粒pDC316-VEGF-C siRNA-EGFP-U6,再与骨架质粒pBHGF35共转染293细胞,同源重组,酶切鉴定,包装扩增后得到重组腺病毒Ad5F35-VEGF-C siRNA-EGFP-U6。裸鼠皮下注射LoVo细胞构建人类结肠癌皮下移植瘤模型24只,随机分为4组(每组6只):以腺病毒、空病毒、裸siRNA以及PBS分别进行瘤内原位注射干预,计算肿瘤体积变化并绘制生长曲线,使用抗LYVE-1单抗和抗CD34单抗分别染色瘤内的血管和淋巴管,检测瘤内淋巴管和血管生成情况,计算微血管密度(MVD),微淋巴管密度(LVD)。结果腺病毒组肿瘤体积明显小于其他各组,腺病毒组与PBS对照组LVD分别为8.47±2.1,17.35±4.7(P〈0.05),腺病毒组与PBS对照组MVD分别为22.65±6.04,23.19±7.63(P〉0.05)。结论实验设计并合成的腺病毒载体介导的VEGF-C siRNA,在人类结肠癌裸鼠移植瘤模型中,瘤内注射腺病毒载体能显著抑制移植瘤的生长和肿瘤淋巴管生成,而对肿瘤血管生长无显著影响。 Objective To construct recombinant adenovirus containing small interfering RNA (siRNA) targeting human VEGF-C mRNA, then to study the inhibitory effects of adenovirus-mediated VEGF- C siRNA on growth and lymphangiogenesis of human colon cancer in BABL/c nude mice model.Methods In vitro: the specific siRNA sequence targeting human VEGF-C mRNA was selected .The homologous doublestrand DNA was designed and synthesized. After such DNA was inserted into pDC316-EGFP-U6 by BamHI and HindⅢ, pDC316-VEGF-C siRNA-EGFP-U6 was obtained, then it was co-transfected into 293 cells with the bone plasmid pBHGF35. After generated by homologous recombination, Ad5F35-VEGF-C siRNA- EGFP-U6 was obtained, and it was packaged and amplified in 293 cells. The human colon cancer model was established in nude mice by hypo-injection LoVo cells. They were divided randomly into four groups (n=6): adenovirus,virus without target gene, single siRNA and PBS control group. Injecting intervention intra-tumorly in each groups, calculating the tumors volume and drawing the growth curve, calculating micro-vascular density (MVD) and micro-lymphatic density (LVD) by staining respectively of the lymphatic and vascular with anti-LYVE-1 monoclonal antibody and anti-CD34 monoclonal antibody were completed. Results Adenovirus group tumor sizes were smaller than other groups. The LVD were 8.47±2.1 and 17.35±4.7 (P 〈0.05) in adenovirus group and the PBS control group.The MVD were 22.65±6.04 and 23.19±7.63 (P 〉0.05) in adenovirus group and the PBS control group respectively. Conclusion The adenovirus-mediated VEGF-C siRNA can significantly inhibit the growth and lymphangiogenesis of human colon cancer in nude mice model, but have no effect on microangium vessels growth.
出处 《肿瘤研究与临床》 CAS 2009年第2期80-83,共4页 Cancer Research and Clinic
基金 宁波市医学科学计划(2006007) 苏州市科技社会发展基金(SSY0628)
关键词 血管内皮生长因子C 腺病毒载体 RNA干扰 淋巴管生成 Vascular endothelial growth factor C Adenovirus vector RNA interference Lymphangiogenesis
  • 相关文献

参考文献18

  • 1Ng P, Parks RJ, Cummings DT. A high efficiency Cre/loxP based system for construction of adenoviral vectors. Hum Gene Ther, :1999, 10: 2667-2672.
  • 2Waisbourd M, Loewenstein A, Goldstein M, et al. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging, 2007, 24: 643-662.
  • 3He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta, 2004, 1654(1): 3-12.
  • 4Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 98: 413-423.
  • 5Sunny Y, Herbert H, Denise C. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis but lymphangiogenesis is unnecessary for lymphnode metastasis. Caner Res, 2005, 65: 9789-9795.
  • 6Goldman J, Rutkowski JM, Shields JD, et al. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J, 2007, 21: 1942.
  • 7Mashino K, Sadanaga N, Yamaguchi H, et al.Expression of chemokine receptor CCR7 is associated with lymph node metastasis in gastric carcinoma. Cancer Res, 2002, 62: 2937-2941.
  • 8Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med, 2001, 7: 192-198.
  • 9Hung C J, Ginzinger DG, Zarneger R, et al. Expression of vascular endothelial growth factor,C in benign and malignant thyroid tumors. J Clin Endoerinol Meta, 2003, 88: 3694-3699.
  • 10Onogawa S, Kitadai Y, Tanaka S, et al. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymphnode metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci, 2004, 95: 32-39.

二级参考文献35

  • 1Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med, 1996, 334: 1649-1655.
  • 2Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension, 1999, 33: 613-621.
  • 3Hannon GJ. RNA interference. Nature, 2002,418:244-251.
  • 4The Runners-Up. Science,2001,294: 2443-2447.
  • 5Donald Kennedy. Breakthrough of the Year. Science, 2001, 294: 2429.
  • 6Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature,2001, 411: 494-498.
  • 7Ross R. The pathogensis of atheroclerosis:a perspective for the 1990s. Nature, 1993, 362: 801-809.
  • 8Landzberg BR, Frishman WH, Lerrick K. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Prog Cardiovasc Dis,1997, 39: 361-398.
  • 9Zhu ZM, Zhang SH, Wagner C, et al. Angiotensin AT1B receptor mediates calcium signaling in vascular smooth muscle cells of AT1A receptor-deficient mice . Hypertension, 1998, 31: 1171-1177.
  • 10Harborth J, Elbashir SM, Bechert K, et al. Identification of essential genes in cultured mammalian cells using small interfering RNAs . J Cell Science, 2001, 114: 4557-4565.

共引文献11

同被引文献30

  • 1Yi-TaoJia,Zhong-XinLi,Yu-TongHe,WeiLiang,Hui-ChaiYang,Hong-JunMa.Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer[J].World Journal of Gastroenterology,2004,10(22):3261-3263. 被引量:28
  • 2Althuis MD, Dozier JM, Anderson WF, et al. Global trends in breastcancer incidence and mortality 1973-1997. Int J Epidemiol, 2005, 34:405-412.
  • 3Martelli AM, Faenza I, Billi AM, et al.Intranuclear3 phosphoinositidemetabolism and Akt signaling: new mechanisms for tumorigenesis andprotection against apoptosis? Cell Signal, 2006, 18: 1101-1107.
  • 4Murthy SS, Tosolini A, Taguchi T, et al. Mapping of AKT3, encoding amember of the Akt/protein kinase B family, to human and rodentchromosomes by fluorescence in situ hybridization. Cell Genet, 2000,88: 38-40.
  • 5Testa JR, Bellacosa. AKT piays a central role in tumorgenesis.ProcNatl Acad Sci USA, 2001,98: 10983-10985.
  • 6Nelson PA, Powers JN, Estridge TD, et al. Serological analysis ofpatients treated with a new surgical hemostat containing bovineproteins and autologous plasma. J Biomed Mater Res, 2001, 58: 710-719.
  • 7Yoeli-Lerner M, Toker A. Akt/PKB signaling in cancer: a function incell motility and invasion. Cell Cycle, 2006, 5: 603-605.
  • 8Itoh N, Semha S, Ito M, et al. Phosphorylation of Akt/PKB is requiredfor suppression of cancer cell apoptosis and tumor progression inhuman colorectal carcinoma. Cancer, 2002, 94: 3127-3134.
  • 9Kurose K, Zhou XP, Araki T, et al. Frequent loss of PTEN expressionis linked to elevated phosphorylated Akt levels, hut not associated withp27 and cyclin D1 expression, in primary epithelial ovariancarcinomas. Am J Pathol, 2001, 158: 2097-2106.
  • 10Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase isfrequently elevated in human cancers and its constitutive activation isrequired for oncogenic transformation in NIH3T3 cells. Am J Pathol,2001, 159:431-437.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部